摘要
目的分析更换含洛匹那韦/利托那韦(LPV/r)二线治疗方案治疗人类免疫缺陷病毒(HIV)感染者/艾滋病(AIDS)患者(简称HIV/AIDS患者)治疗失败的基因型耐药情况。方法收集2014年1月1日至2016年12月31日来自云南省部分接受高效抗逆转录病毒治疗(HAART)的患者治疗信息,筛选出更换含LPV/r的治疗方案且治疗时间大于6个月、治疗期间检测病毒载量大于1 000copy/mL的血浆标本共计162份,对该样本进行基因型耐药检测。结果通过基因型耐药检测共获得符合条件pol区序列162条,该人群中耐药发生率为40.1%(65/162)。在使用过的药物中,耐药率较高的几个药物分别是奈韦拉平(NVP)、依非韦伦(EFV)、拉米夫定(3TC)、恩曲他宾(FTC),发生高度耐药的患者分别有45例(27.8%)、35例(21.6%)、26例(16.0%)、26例(16.0%)。结论云南省部分更换含LPV/r抗病毒治疗失败患者的耐药率相对较低,但部分患者出现了包括LPV/r在内的多重耐药。
Objective To analyze the genotype drug resistance situation in the failure for treating the HIV infected persons/AIDS patients by replacing the second line treatment regimen containing lopinavir/ritonavir(LPV/r).Methods The treatment information of the partial patients receiving the highly active antiretroviral therapy(HAART)in Yunnan Province from January 1 2014 to December 31 2016 was collected and 162 plasma samples of replacing treatment regimen containing LPV/r,treatment time>6 months and the viral loads>1 000 copy/mL detected in treatment process were screened out,their genotype drug-resistance detection was performed.Results One hundred and sixty-two strips of pol region sequence in according with the condition were totally obtained by using the genotype drug resistance detection and the incidence rate of drug resistance in this population was 40.1%(65/162).Among the used drugs,the drugs of high drug resistance rate were NVP,EFV,3TC and FTC,the partial patients developing high drug-resistance had 45 cases(27.8%),35 cases(21.6%),26cases(16.0%)and 26 cases(16.0%)respectively.Conclusion The drug resistance rate in the patients with failure by replacing the antiviral treatment regimen containing LPV/r is relatively low.But the partial patients appeared the multiple drug resistance including LPV/r.
作者
刘家法
张米
李健健
杨壁珲
邓雪媚
雷素云
LIU Jiafa;ZHANG Mi;LI Jianjian;YANG Bihui;DENG Xuemei;LEI Suyun(Yunnan Provincial Hospital of Infectious Disease/AIDS Care Center,Kunming,Yunnan 650301,China)
出处
《重庆医学》
CAS
2018年第34期4399-4402,共4页
Chongqing medicine
基金
云南省科技计划项目(2016BC005)
云南省教育厅科学研究基金项目(2018JS252)
